Paradis
AI & Technology Investment Research
IQE is reaching its financial inflection point as InP demand for AI and data centers drives growth. It raised 2026 revenue growth guidance from 20% to over 30% after H1 revenue of £64m versus £45m, and forecasts low-teens £m adjusted EBITDA. MACOM's investment left it debt-free with £42m of cash. The 30% target looks deliberately conservative after past over-optimism; as @mkfilko notes, it implies H2 revenue below H1, which seems unlikely. x.com x.com
IQE is one of the only Western epi houses that can supply InP epiwafers at meaningful scale, and InP sits under every data-center optical interconnect. News since May has been net positive: a multi-year Tower Semiconductor InP deal with minimum purchase commitments, a $14M AI/data-center order and a £45M MACOM investment that repaired the balance sheet. The drop looks like a post-parabolic reset. Risks include past execution issues, dilution history and Chinese export curbs raising input costs. x.com
InP substrate demand and pricing still support the AI optics supply chain. Yunnan Germanium reports higher InP volumes from AI data centers and optical communications, plus higher prices. Q3 revenue rose 134.6% year on year, near AXT's guided 136%, but also includes germanium. IQE's H1 photonics grew 45%, partly from US defense funding. AXT's $66m Q3 guide covers only licensed exports or sales needing no license; a miss would more likely reflect licensing. x.com
IQE's new multi-year indium phosphide epiwafer supply deal with Tower Semiconductor puts a 5x-10x move from March 2026 levels in the works, and IQE is the pick over Tower itself. Per Wall St Engine, the wafers support Tower's silicon photonics platforms for AI data center optics, including 200G/lane pluggable transceivers, 400G/lane modulator prototypes and optical circuit switches. The two also settled their IP dispute, with Tower granting IQE a worldwide royalty-free license. x.com x.com
IQE is hard to call undervalued because its price already embeds a mature-margin scenario two-plus years out. At a 15% margin and 20% yearly growth, FY28 EBITDA is about GBP25 million, worth about GBP500 million at a generous 20x, versus a GBP520 million market cap at 40p. IQE earns about 3% adjusted EBITDA margins versus LandMark's high-margin epi, MACOM's convertible and warrants carry about 76 million shares of overhang, and InP supply constraints threaten its H2-weighted guide. x.com x.com … Show more
IQE's overhang has cleared: its £81 million raise is complete and brings in MACOM as a heavyweight strategic investor. The money goes straight to repaying debt, easing the balance-sheet pressure the market feared most, and the strategic review has ended, so IQE is no longer in limbo as a sale candidate. As the global leader in compound semiconductor epiwafers, its position in AI infrastructure, especially HBM4, and 5G is irreplaceable, and the valuation repair is just beginning. x.com
IQE's new multi-year InP epiwafer supply deal with Tower Semiconductor shows its product is irreplaceable, adding a third Tier-1 foundry anchor in the AI photonics stack after Lumentum and MACOM. IQE is the non-Chinese InP source Tower needed, a geopolitical moat, and is designed into the optical roadmap from 200G pluggables to 400G-per-lane modulators and optical circuit switches. Tower, which IQE sued for IP theft in 2022, even granted IQE a royalty-free patent license. x.com
IQE is held above its fundamental fair value by optimistic expectations, and its takeover thesis is effectively dead. With MACOM as anchor investor holding board seats and exclusive long-term supply deals, a bidding war is practically ruled out. The 19.8p placing, a 58% discount, takes dilution since early 2025 to about 42%, and the £81 million mostly repays debt, so capex needs another raise within 18-24 months. If momentum fades the stock will fall; if it strengthens, it can keep rising. x.com
IQE still has plenty of upside as Tower Semiconductor's indium phosphide epitaxial wafer supplier for the NPO-to-CPO buildout. Tower said its multi-year epi wafer agreement with IQE leaves it extremely well positioned against the InP bottleneck. Tower's first NPO deployments come in 2027, with $1.3B of contract value for that year and higher numbers expected after, and it plans to quadruple Japanese silicon photonics capacity, with full readiness in Q4 2027. x.com x.com x.com
IQE has its clarity restored now that its strategic review is done, and Deutsche Bank has rated it a Buy with a 60p target. AI data center demand is very strong, defense and satellite communications are ramping, and an £81M raise closes at the end of June. Compound semiconductor materials are the backbone of the AI era. x.com
IQE's bottleneck position in AI optics is already priced in, so the easy money is gone until its revenue and profits grow. Per @jpinsights, IQE grows the indium phosphide epiwafers high-speed lasers are built from, and validation came through MACOM's GBP45m investment, Tower's multi-year supply deal and a GBP81m raise. But the stock has rerated hard, and it is unclear whether any of this has reached IQE's own numbers. x.com
IQE's rerating case around converting latent capacity toward AI data-center products looks validated by management's latest comments. The main cost of conversion is tool downtime rather than heavy investment, and IQE converts tools only with customer commitments and secured demand. Its main concern remains resolving indium-phosphide substrate constraints. x.com
